A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (NCT06183931)
DepleTTR-CM
This trial is No longer recruiting
Registration number NCT06183931
Program & service
This trial is being run with the Heart & Lung service, and as part of the Cardiology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
A/Prof James Hare
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR